Recro Pharma found using ticker (REPH) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 10 and 5 calculating the average target price we see 7.5. Now with the previous closing price of 2.97 this would imply there is a potential upside of 152.5%. The day 50 moving average is 2.28 and the 200 day moving average is 3.02. The market capitalisation for the company is $78m. Find out more information at: http://www.recropharma.com
Recro Pharma a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products to pharmaceutical market in the United States and internationally. The company was formerly known as Recro Pharma I and changed its name to Recro Pharma in August 2008. Recro Pharma was founded in 2007 and is based in Malvern, Pennsylvania.